Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Selective T-cell deletion refers to the physiological removal of self-reactive or undesirable T-cell clones from the immune repertoire. This typically occurs in the thymus (central tolerance) via clonal deletion—where T cells with high-affinity recognition of self-antigens presented by thymic antigen-presenting cells undergo apoptosis—and can also occur in peripheral tissues (peripheral tolerance)[1][3][7]. This process is crucial for preventing autoimmunity and promoting immune homeostasis. While not a therapeutic target itself, the mechanisms underlying selective T-cell deletion are researched for interventions in autoimmunity, transplant tolerance, and immuno-oncology[1][2][5].
Induction of T-cell apoptosis via high-affinity self-antigen recognition on MHC complexes, leading to clonal deletion[1][3][5][7]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Selective T-cell deletion.